Firm consolidation, thoughtful staffing, disciplined scope control, and performance accountability can save life sciences ...

Emerging biotechs and their investors are exploring partnerships with drug companies at much earlier stages. Experts at ...

On this week's episode, Joel Latham, President and CEO at Incannex Healthcare, talks about developing cannabinoid and psychedelic combination therapies for conditions as diverse as sleep apnea, ...

We stand at an extraordinary crossroads in medicine. This year, a young patient at Children's Hospital of Philadelphia received a treatment that would have been pure science fiction just decades ago — ...

Recently, the first patient in history was treated with an epigenetic editing therapy for facioscapulohumeral muscular dystrophy (FSHD). It was an extraordinary scientific milestone, but more ...

As the life sciences industry grapples with the demands of AI and the need to integrate real-world evidence into increasingly complex pipelines, the FAIR data principles — Findable, Accessible, ...

Neurological diseases now represent the leading cause of disability worldwide, with trial activity in this area growing rapidly — neurology studies increased 76% between 2015 and 2024 alone. Yet ...

On this week's Business Of Biotech episode, Atul Deshpande, Ph.D., CEO at Immediate Therapeutics, talks about partnering with American cities to conduct clinical trials during ambulance rides to the ...

Decades of technological innovation and scientific advances have revolutionized the treatment paradigm for many conditions that have long eluded conventional therapies. Advanced viral vector-based ...

Vaccines that use protein subunits or recombinant vectors are now the most common types of vaccines in development for infectious diseases and cancer, as they are relatively easy to produce and can be ...

This is Episode 4 of "FDA Fridays," a special series from Cell & Gene: The Podcast, Chief Editor Erin Harris speaks with regulatory affairs expert Daniela Drago, Partner, NDA Partners, about how ...

Oncolytic viruses (OVs) are natural or recombinant attenuated versions of common viruses that do not cause disease but instead infect tumor cells preferentially over healthy cells. The virus ...